



Cartesian Therapeutics Announces Appointment of Three World-Renowned Scientists and Engineers as Charter Members of Company's Scientific Advisory Board

April 25, 2023

Gaithersburg, MD—April 25, 2023– Cartesian Therapeutics, a fully integrated biopharmaceutical company pioneering RNA cell therapy for autoimmune diseases and cancer, today announced the appointment of three world-renowned scientists and engineers as charter members of the company's Scientific Advisory Board (SAB): Prof. Jennifer Elisseeff (Johns Hopkins University), Prof. Andrés García (Georgia Institute of Technology), and Prof. David Mooney (Harvard University).

"These distinguished research leaders bring vast experience across cell engineering, translational medicine, drug delivery, and technology development," said Christopher M. Jewell, PhD, Chief Scientific Officer at Cartesian Therapeutics. "Their perspectives will be invaluable as Cartesian develops novel RNA cell therapies to treat autoimmune diseases and cancer".

The biographies of the new SAB members are as follows:

Andrés J. García, PhD is the Executive Director of the Petit Institute for Bioengineering and Bioscience and Regents' Professor at the Georgia Institute of Technology. He is a co-founder of three successful start-up companies and an elected member of the National Academy of Engineering, the National Academy of Medicine, and the National Academy of Inventors. His research program integrates innovative engineering and cell biology concepts to create cell-instructive technologies for regenerative medicine and cell engineering. Dr. García has published hundreds of papers in these areas and received many distinctions, including Georgia Tech's Class of 1934 Distinguished Professor Award and the Founders Award from the Society for Biomaterials.

Jennifer H. Elisseeff, PhD is the Morton Goldberg Professor and Director of the Translational Tissue Engineering Center at Johns Hopkins University Department of Biomedical Engineering and the Wilmer Eye Institute, with appointments in Chemical and Biological Engineering, Orthopedic Surgery, and Materials Science. She is a Fellow of the National Academy of Inventors, the National Academy of Engineering, the National Academy of Medicine, and the American Academy of Arts and Sciences. Dr. Elisseeff's research focuses on the impacts of immune and stromal environments on complex tissue during disease and tissue repair. In these areas she has founded several successful startups and published hundreds of peer reviewed studies.

David J. Mooney, PhD is the Pinkas Family Professor of Bioengineering in the Harvard School of Engineering and Applied Sciences and a Core Faculty Member of the Wyss Institute. His laboratory designs advanced technologies for immunotherapy and regenerative medicine. Dr. Mooney's efforts have led to hundreds of papers in peer-reviewed journals. He is a member of the National Academy of Engineering, the National Academy of Medicine, and the National Academy of Inventors. His inventions have been licensed by over 20 companies, leading to several commercialized products. Dr. Mooney has founded a number of successful companies and is active on many industry scientific advisory boards.

About Cartesian Therapeutics

Cartesian is pioneering RNA cell therapies for autoimmune diseases and cancer. The company's lead asset, Descartes-08, is a first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase 2b clinical development for patients with generalized myasthenia gravis. Cartesian operates a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD. For more information visit www.cartesiantherapeutics.com.